With the recent announcement of a significant licensing deal with AGC Ltd in Japan, the company is set to build on their platform for the delivery of Progenza to deal with many healthcare issues from arthritis and pain, to genetic disorders.
Rhinomed (ASX:RNO) is pleased to provide an update on the expansion of its global distribution program. The company can report that Rhinomed has been added as a vendor by two major US based pharmacy wholesalers and the successful expansion of the listing of its Mute Sleep technology by Symbion in Australia.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the Company's Half Yearly Report for the period ended 31 December, 2016.
Immuron Limited (ASX:IMC) (OTCMKTS:IMROY) wishes to advise investors that European and US-based Life Sciences Research and Analyst firm Van Leeuwenhoeck Institute, has published an updated in-depth Research Report on the Company and its R&D programs.
Imugene Limited (ASX:IMU) preclinical research related to HER-Vaxx (clinical name IMU-131) has been accepted and published in the prestigious journal BMC Cancer. IMU-131 is a next generation HER-2 cancer therapy using B cell peptides, which harness the body's ability to develop antibodies against the disease.
Dotz Nano Ltd (ASX:DTZ) has successfully completed a Proof of Concept research study into the use of Graphene Quantum Dots (GQDs) in flash memory with the Kyung Hee University in South Korea. Dotz Nano is in advanced negotiations to sign a full licensing agreement with Kyung Hee University.
Immuron Limited (ASX:IMC) (OTCMKTS:IMROY), an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products to target inflammatory-mediated diseases, today announced that Emory University has enrolled its first patient in Immuron's IMM-124E pediatric NAFLD Phase II trial.
